Please select the option that best describes you:
How would you treat a patient presenting with de novo metastatic prostate cancer and baseline low testosterone?
If baseline testosterone is at castrate levels (e.g. <50), would you consider patient to have castrate-resistant disease?
Answer from: Medical Oncologist at Academic Institution
By definition, progressive disease despite castrate levels of testosterone is CRPC. This is a very rare situation in the de novo setting, and more likely one may encounter a patient with only slightly low testosterone, which would not be considered CRPC. Patients with de novo metastatic prostate can...
Sign in or Register to read more